The substantial weight loss achieved with GLP-1 receptor agonists and dual GIP/GLP-1 agonistsapproximately 15% with semaglutide 2.4 mg (Wegovy) and up to 21% with higher doses of tirzepatide (Zepbound) in clinical trialsoccurs primarily through appetite suppression and reduced caloric intake rather than increased metabolic rate
Promoting it can lead to eating disorders, body dysmorphia and drug use
Moreover, it reduces pigmentation and stimulates collagen, as per clinical evidence
This dual action improves appetite control, enhances blood sugar regulation, and promotes greater weight loss potential
Tirzepatide can reduce oral contraceptive effectiveness, necessitating backup contraception for 4 weeks after starting or increasing doses
The right procedure is determined by a patient and their doctor, after a through review of medical history, and weight loss goals